Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

5-AMINOSALICYLIC ACID

Form:

17 of 17 products shown

16 general benefit · 1 not a benefit

Other products in the same Health Canada class (A07E, A07EC) — coverage varies; not interchangeable

  • Mesalazine (Octasa): general benefit
  • Olsalazine (Dipentum): general benefit
  • Budesonide (Uceris): general benefit

Mezera · DIN 02474026 · 1g/Actuation · 14 Actuation-Foam Enema Canister Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Mezera · DIN 02474026 Manufacturer: Avir Pharma Inc.; listing date 2020-05-29 Health Canada: Marketed since 2018-07-13 · brand MEZERA · ATC A07EC02 MESALAZINE · form Foam · route Rectal · ingredients MESALAZINE 1 G/ACT · company Avir pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

Mezera: Formulary list price $103.8600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $103.8600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96403 · Verify on the e-Formulary ↗ (DIN 02474026)

Source record
DIN 02474026: Mezera Raw flags: sec3=Y Item: 564000137; group id 672; item number 1667; lccId None; manufacturer id AVP Source form: 14 Actuation-Foam Enema Canister Pk; strength: 1g/Actuation Recorded listing: General benefit Source prices (unrounded): $103.8600; ministry $103.8600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474026 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96403
Shortage status: resolved shortage (ended 2019-03-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474026
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mezera · DIN 02545012 · 1g · DR tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Mezera · DIN 02545012 Manufacturer: Avir Pharma Inc.; listing date 2025-04-30 Health Canada: Marketed since 2024-07-26 · brand MEZERA · ATC A07EC02 MESALAZINE · form Tablet (delayed-release) · route Oral · ingredients MESALAZINE 1 G · company Avir pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

Mezera: Formulary list price $1.3011/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.3011 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103363 · Verify on the e-Formulary ↗ (DIN 02545012)

Source record
DIN 02545012: Mezera Raw flags: sec3=Y Item: 564000145; group id 672; item number 1670; lccId None; manufacturer id AVP Source form: DR Tab; strength: 1g Recorded listing: General benefit Source prices (unrounded): $1.3011; ministry $1.3011 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02545012 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103363
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02545012
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pentasa · DIN 02399466 · 1g · extended release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Pentasa · DIN 02399466 Manufacturer: Ferring Inc.; listing date 2013-11-28 Health Canada: Marketed since 2013-03-12 · brand PENTASA · ATC A07EC02 MESALAZINE · form Tablet (extended-release) · route Oral · ingredients MESALAZINE 1 G · company Ferring inc · schedule Prescription
Check this DIN again · Health Canada product record

Pentasa: Formulary list price $1.5540/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.5540 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88434 · Verify on the e-Formulary ↗ (DIN 02399466)

Source record
DIN 02399466: Pentasa Raw flags: sec3=Y Item: 564000127; group id 672; item number 1675; lccId None; manufacturer id FEI Source form: ER Tab; strength: 1g Recorded listing: General benefit Source prices (unrounded): $1.5540; ministry $1.5540 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02399466 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88434
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02399466
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pentasa · DIN 02153521 · 1g/100mL · Enema

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Pentasa · DIN 02153521 Manufacturer: Ferring Inc.; listing date 1996-12-19 Health Canada: Marketed since 1999-11-09 · brand PENTASA · ATC A07EC02 MESALAZINE · form Suspension · route Rectal · ingredients MESALAZINE 1 G/100ML · company Ferring inc · schedule Prescription
Check this DIN again · Health Canada product record

Pentasa: Formulary list price $6.8600/unit (unit not stated in source; not the patient's cost)

Ministry pays: $6.8600 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18496 · Verify on the e-Formulary ↗ (DIN 02153521)

Source record
DIN 02153521: Pentasa Raw flags: sec3=Y Item: 564000075; group id 672; item number 1672; lccId None; manufacturer id FEI Source form: Enema; strength: 1g/100mL Recorded listing: General benefit Source prices (unrounded): $6.8600; ministry $6.8600 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02153521 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18496
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02153521
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mezera · DIN 02474018 · 1g · suppository

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Mezera · DIN 02474018 Manufacturer: Avir Pharma Inc.; listing date 2019-08-30 Health Canada: Marketed since 2018-07-13 · brand MEZERA · ATC A07EC02 MESALAZINE · form Suppository · route Rectal · ingredients MESALAZINE 1 G · company Avir pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

Mezera: Formulary list price $1.9076/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.9076 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96402 · Verify on the e-Formulary ↗ (DIN 02474018)

Source record
DIN 02474018: Mezera Raw flags: sec3=Y Item: 564000136; group id 672; item number 1677; lccId None; manufacturer id AVP Source form: Sup; strength: 1g Recorded listing: General benefit Source prices (unrounded): $1.9076; ministry $1.9076 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02474018 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96402
Shortage status: resolved shortage (ended 2021-06-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02474018
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pentasa · DIN 02153564 · 1g · suppository

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Pentasa · DIN 02153564 Manufacturer: Ferring Inc.; listing date 1996-12-19 Health Canada: Marketed since 1999-11-09 · brand PENTASA · ATC A07EC02 MESALAZINE · form Suppository · route Rectal · ingredients MESALAZINE 1 G · company Ferring inc · schedule Prescription
Check this DIN again · Health Canada product record

Pentasa: Formulary list price $2.7020/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.7020 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18493 · Verify on the e-Formulary ↗ (DIN 02153564)

Source record
DIN 02153564: Pentasa Raw flags: sec3=Y Item: 564000074; group id 672; item number 1679; lccId None; manufacturer id FEI Source form: Sup; strength: 1g Recorded listing: General benefit Source prices (unrounded): $2.7020; ministry $2.7020 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02153564 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18493
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02153564
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mezavant · DIN 02297558 · 1.2g · Delayed & extended release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Mezavant · DIN 02297558 Manufacturer: Takeda Canada Inc.; listing date 2009-04-01 Health Canada: Marketed since 2021-11-22 · brand MEZAVANT · ATC A07EC02 MESALAZINE · form Tablet (delayed- and extended-release) · route Oral · ingredients MESALAZINE 1.2 G · company Takeda canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Mezavant: Formulary list price $2.0520/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0520 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78289 · Verify on the e-Formulary ↗ (DIN 02297558)

Source record
DIN 02297558: Mezavant Raw flags: sec3=Y Item: 564000107; group id 672; item number 1669; lccId None; manufacturer id TAK Source form: Delayed & ER Tab; strength: 1.2g Recorded listing: General benefit Source prices (unrounded): $2.0520; ministry $2.0520 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02297558 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78289
Shortage status: resolved shortage (ended 2026-07-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02297558
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pentasa · DIN 02153556 · 4g/100mL · Enema

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Pentasa · DIN 02153556 Manufacturer: Ferring Inc.; listing date 1996-12-19 Health Canada: Marketed since 1999-11-08 · brand PENTASA · ATC A07EC02 MESALAZINE · form Suspension · route Rectal · ingredients MESALAZINE 4 G/100ML · company Ferring inc · schedule Prescription
Check this DIN again · Health Canada product record

Pentasa: Formulary list price $9.4700/unit (unit not stated in source; not the patient's cost)

Ministry pays: $9.4700 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18494 · Verify on the e-Formulary ↗ (DIN 02153556)

Source record
DIN 02153556: Pentasa Raw flags: sec3=Y Item: 564000077; group id 672; item number 1673; lccId None; manufacturer id FEI Source form: Enema; strength: 4g/100mL Recorded listing: General benefit Source prices (unrounded): $9.4700; ministry $9.4700 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02153556 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18494
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02153556
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Salofalk · DIN 02112809 · 4g · Rect suspension-Pk

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Salofalk · DIN 02112809 Manufacturer: Axcan Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2024-06-12 · brand SALOFALK · ATC A07EC02 MESALAZINE · form Suspension · route Rectal · ingredients MESALAZINE 4 G/60G · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Salofalk: Formulary list price $10.0389/unit (unit not stated in source; not the patient's cost)

Ministry pays: $10.0389 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18509 · Verify on the e-Formulary ↗ (DIN 02112809)

Source record
DIN 02112809: Salofalk Raw flags: sec3=Y Item: 564000034; group id 672; item number 1676; lccId None; manufacturer id BFI Source form: Rect Susp-Pk; strength: 4g Recorded listing: General benefit Source prices (unrounded): $10.0389; ministry $10.0389 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02112809 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18509
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02112809
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-5-ASA · DIN 02171929 · 400mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-5-ASA · DIN 02171929 Manufacturer: Teva Canada Limited; listing date 2008-12-23 Health Canada: Marketed since 2015-05-12 · brand TEVA-5 ASA · ATC A07EC02 MESALAZINE · form Tablet (enteric-coated) · route Oral · ingredients MESALAZINE 400 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-5-ASA: Formulary list price $0.4758/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4758 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19524 · Verify on the e-Formulary ↗ (DIN 02171929)

Source record
DIN 02171929: Teva-5-ASA Raw flags: sec3=Y Item: 564000030; group id 672; item number 1681; lccId None; manufacturer id TEV Source form: Tab; strength: 400mg Recorded listing: General benefit Source prices (unrounded): $0.4758; ministry $0.4758 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02171929 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19524
Interchangeable products
Asacol · DIN 01997580 · not recorded
Shortage status: resolved shortage (ended 2026-01-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02171929
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mezera · DIN 02524481 · 500mg · DR tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Mezera · DIN 02524481 Manufacturer: Avir Pharma Inc.; listing date 2024-01-31 Health Canada: Marketed since 2022-10-05 · brand MEZERA · ATC A07EC02 MESALAZINE · form Tablet (delayed-release) · route Oral · ingredients MESALAZINE 500 MG · company Avir pharma inc. · schedule Prescription
Check this DIN again · Health Canada product record

Mezera: Formulary list price $0.6760/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.6760 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101350 · Verify on the e-Formulary ↗ (DIN 02524481)

Source record
DIN 02524481: Mezera Raw flags: sec3=Y Item: 564000139; group id 672; item number 1671; lccId None; manufacturer id AVP Source form: DR Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.6760; ministry $0.6760 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524481 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101350
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524481
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Pentasa · DIN 02099683 · 500mg · Del-Release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Pentasa · DIN 02099683 Manufacturer: Ferring Inc.; listing date 1996-10-01 Health Canada: Marketed since 1999-04-01 · brand PENTASA · ATC A07EC02 MESALAZINE · form Tablet (extended-release) · route Oral · ingredients MESALAZINE 500 MG · company Ferring inc · schedule Prescription
Check this DIN again · Health Canada product record

Pentasa: Formulary list price $0.7770/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7770 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16855 · Verify on the e-Formulary ↗ (DIN 02099683)

Source record
DIN 02099683: Pentasa Raw flags: sec3=Y Item: 564000049; group id 672; item number 1668; lccId None; manufacturer id FEI Source form: Del-Release Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.7770; ministry $0.7770 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02099683 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=16855
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02099683
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Salofalk · DIN 02112787 · 500mg · enteric-coated tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Salofalk · DIN 02112787 Manufacturer: Axcan Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2024-01-23 · brand SALOFALK · ATC A07EC02 MESALAZINE · form Tablet (delayed-release) · route Oral · ingredients MESALAZINE 500 MG · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Salofalk: Formulary list price $0.7685/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7685 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18214 · Verify on the e-Formulary ↗ (DIN 02112787)

Source record
DIN 02112787: Salofalk Raw flags: sec3=Y Item: 564000045; group id 672; item number 1674; lccId None; manufacturer id BFI Source form: Ent Tab; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $0.7685; ministry $0.7685 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02112787 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18214
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02112787
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Salofalk · DIN 02112760 · 500mg · suppository

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Salofalk · DIN 02112760 Manufacturer: Axcan Pharma Inc.; listing date 1996-10-01 Health Canada: Marketed since 2024-07-10 · brand SALOFALK · ATC A07EC02 MESALAZINE · form Suppository · route Rectal · ingredients MESALAZINE 500 MG · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Salofalk: Formulary list price $1.8896/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.8896 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18212 · Verify on the e-Formulary ↗ (DIN 02112760)

Source record
DIN 02112760: Salofalk Raw flags: sec3=Y Item: 564000039; group id 672; item number 1678; lccId None; manufacturer id BFI Source form: Sup; strength: 500mg Recorded listing: General benefit Source prices (unrounded): $1.8896; ministry $1.8896 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02112760 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=18212
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02112760
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Salofalk · DIN 02242146 · 1000mg · suppository

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Salofalk · DIN 02242146 Manufacturer: Axcan Pharma Inc.; listing date 2005-09-27 Health Canada: Marketed since 2024-03-28 · brand SALOFALK · ATC A07EC02 MESALAZINE · form Suppository · route Rectal · ingredients MESALAZINE 1000 MG · company Abbvie corporation · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $1.4005 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65824 · Verify on the e-Formulary ↗ (DIN 02242146)

Source record
DIN 02242146: Salofalk Raw flags: sec3=Y Item: 564000100; group id 672; item number 1680; lccId None; manufacturer id BFI Source form: Sup; strength: 1000mg Recorded listing: General benefit Source prices (unrounded): $2.7754; ministry $1.4005 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242146 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=65824
Interchangeable products
ZDS-Mesalamine Suppositories · DIN 02562367 · $1.4005
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242146
Shortage record checked 2026-09-13T08:10:21.292534+00:00

ZDS-Mesalamine Suppositories · DIN 02562367 · 1000mg · suppository

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
ZDS-Mesalamine Suppositories · DIN 02562367 Manufacturer: Zydus; listing date 2026-05-29 Health Canada: Marketed since 2026-03-11 · brand ZDS-MESALAMINE SUPPOSITORIES · ATC A07EC02 MESALAZINE · form Suppository · route Rectal · ingredients MESALAZINE 1000 MG · company Zydus lifesciences limited · schedule Prescription
Check this DIN again · Health Canada product record

ZDS-Mesalamine Suppositories: Formulary list price $1.4005/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.4005 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106525 · Verify on the e-Formulary ↗ (DIN 02562367)

Source record
DIN 02562367: ZDS-Mesalamine Suppositories Raw flags: sec3=Y Item: 564000100; group id 672; item number 1680; lccId None; manufacturer id ZDS Source form: Sup; strength: 1000mg Recorded listing: General benefit Source prices (unrounded): $1.4005; ministry $1.4005 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02562367 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106525
Interchangeable products
Salofalk · DIN 02242146 · $1.4005
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02562367
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Asacol · DIN 01997580 · 400mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.Discontinued 2020-07-17 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Asacol · DIN 01997580 Manufacturer: Warner Chilcott Canada Co.; listing date 1996-10-01 Health Canada: Cancelled post market since 2020-07-17 · brand ASACOL · ATC A07EC02 MESALAZINE · form Tablet (enteric-coated) · route Oral · ingredients MESALAZINE 400 MG · company Allergan inc · schedule Prescription
Check this DIN again · Health Canada product record

Asacol: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14552 · Verify on the e-Formulary ↗ (DIN 01997580)

Source record
DIN 01997580: Asacol Raw flags: notABenefit=Y, sec3=Y Item: 564000030; group id 672; item number 1681; lccId None; manufacturer id WAR Source form: Tab; strength: 400mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01997580 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14552
Interchangeable products
Teva-5-ASA · DIN 02171929 · $0.4758
Shortage status: discontinued (2020-07-24, reported by ALLERGAN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01997580
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2020-07-17 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (56:40 Miscellaneous G.I. Drugs) and how they are covered

Matched class: 56:40 Miscellaneous G.I. Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BUDESONIDE, MESALAZINE, NIZATIDINE, OLSALAZINE SODIUM, PANTOPRAZOLE MAGNESIUM, RABEPRAZOLE SODIUM, SUCRALFATE Some products covered without a code (check the product listing): CIMETIDINE, DOMPERIDONE MALEATE, FAMOTIDINE, LACTULOSE, METOCLOPRAMIDE HCL, MISOPROSTOL, RANITIDINE HCL 56:40 Miscellaneous G.I. Drugs

MESALAZINE

· 2 products · General benefit · strengths: 800mg, 1600mg · DR Tab

OLSALAZINE SODIUM

· 1 products · General benefit · strengths: 250mg · Cap

BUDESONIDE

· 1 products · General benefit · strengths: 2mg/Act · Rectal Foam-14 Act Canister

CIMETIDINE

· 10 products · General benefit (5), Listed, not a benefit (5) · strengths: 200mg, 300mg, 400mg, 600mg, 800mg · Tab

DOMPERIDONE MALEATE

· 11 products · Listed, not a benefit (1), General benefit (10) · strengths: 10mg · Tab

FAMOTIDINE

· 16 products · Listed, not a benefit (2), General benefit (14) · strengths: 20mg, 40mg · Tab

LACTULOSE

· 7 products · General benefit (6), Listed, not a benefit (1) · strengths: 667mg/mL · O/L

METOCLOPRAMIDE HCL

· 8 products · Limited Use, codes 481, 657 (2), Listed, not a benefit (2), General benefit (4) · strengths: 5mg/mL, 5mg, 10mg · Inj Sol (Preservative Free), Tab

MISOPROSTOL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 100mcg, 200mcg · Tab

NIZATIDINE

· 2 products · General benefit · strengths: 150mg, 300mg · Cap

PANTOPRAZOLE MAGNESIUM

· 6 products · General benefit · strengths: 40mg · Ent Coated Tab

RABEPRAZOLE SODIUM

· 16 products · General benefit · strengths: 10mg, 20mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:40 and 10 more
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:22 Antiemetics and Antinauseants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1. Indications PENTASA (mesalazine) extended-release tablets are indicated for: • Treatment of mild to moderate active ulcerative colitis and for long-term maintenance therapy in order to maintain remission and prevent relapse of active disease. • Management of mild to moderate Crohn’s Disease and maintenance of Crohn’s Disease in remission induced by surgery or medication PENTASA (mesalazine) rectal suspension is indicated for: • Treatment of acute distal ulcerative colitis extending to the splenic flexure and for long-term maintenance therapy in order to maintain remission and prevent relapse of active disease. Clinical experience has shown that topical PENTASA (i.e. enemas/suppositories) is superior to oral PENTASA (i.e. tablets) with regard to therapeutic efficacy in distal ulcerative colitis (Table 3 - Clinical experience from pivotal trials). PENTASA (mesalazine) suppositories are indicated for: • Treatment of acute ulcerative proctitis and for long-term maintenance therapy in order to maintain remission and prevent relapse of a… https://pdf.hres.ca/dpd_pm/00084316.PDF PM date: 2026-04-16 Source product: PENTASA; DIN 02099683; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Salofalk · DIN 02112809 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02112809

Check this DIN again

Salofalk · DIN 02112760 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02112760

Check this DIN again

Salofalk · DIN 02242146 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242146

Check this DIN again

Asacol · DIN 01997580 Shortage status: discontinued (2020-07-24, reported by ALLERGAN INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01997580

Check this DIN again

Other review policies

For Asacol: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026